S1806

SWOG/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer

Principal Investigator

Jason Efstathiou, MD, Dphil

Status

Disease Site

Genitourinary [GU] Bladder

Phase

III

Developmental Therapeutics

No

Primary Objective

To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).

NOTE:

This is a Joint SWOG & NRG Oncology FDA registration-intent trial. NRG Oncology institutions can credit NRG for their case accrual. NRG Canadian member sites must credit the Canadian Clinical Trials Group (CCTG). 

SWOG Study Chair: Parminder Singh, M.D.

Patient Population

Patients with muscle invasive bladder cancer (MIBC) (T2-T4aN0M0).

Target Accrual

475